Module 3.2.P — Drug Product (Full) — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 3.2.P — the full drug product (finished dosage form) section: formulation, manufacture, control, and stability.
Why it exists. The finished IV and oral products, not just the raw molecule, are what patients receive. This section documents the formulation, how the product is made and tested, and its shelf life.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q · Q8(R2) · Q6B · Q1A(R2)/Q1B · Q3B(R2)/Q3C/Q3D · Q2(R2) · Q7
Module 3.2.P — Drug Product (Full) — GLPI-103
| Field | Value |
|---|---|
| Document ID | M3-P |
| Version | 3.0 (full, expanded) |
| Standard | ICH M4Q · Q8(R2) · Q6B · Q1A(R2)/Q1B · Q3B(R2)/Q3C/Q3D · Q2(R2) · Q7 |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Full drug-product section (P.1–P.8) for the two GLPI-103 presentations: (A) a sterile solution for intravenous injection (once weekly) and (B) an immediate-release oral tablet with a permeation enhancer (once daily). Values are illustrative but technically representative.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0–2.0 | 2026-06-29 | CMC | Initial / schematic full |
| 3.0 | 2026-06-30 | CMC | Expanded — explicit compositions, pharmaceutical development rationale (oral peptide permeation), manufacturing & controls, specifications with limits, batch & stability data, container-closure |
P.1 Description and Composition
(A) Solution for injection (IV), 4 mg/mL — clear, colourless to slightly yellow sterile solution in a Type I glass cartridge (pen) / vial:
| Component | Function | Quantity (per mL) |
|---|---|---|
| GLPI-103 (as acetate) | Active | 4.0 mg |
| Disodium phosphate dihydrate | Buffer (pH 7.4) | 1.42 mg |
| Sodium chloride | Tonicity | 8.0 mg |
| Phenol | Antimicrobial preservative (multidose) | 5.5 mg |
| Polysorbate 80 | Stabiliser (anti-aggregation) | 0.2 mg |
| Hydrochloric acid / sodium hydroxide | pH adjustment | q.s. pH 7.2–7.6 |
| Water for injection | Vehicle | q.s. to 1 mL |
(B) Tablet (oral), 8 mg — immediate-release tablet containing a permeation enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, SNAC) enabling gastric absorption of the peptide:
| Component | Function | mg/tablet |
|---|---|---|
| GLPI-103 (as acetate) | Active | 8.0 |
| SNAC | Permeation enhancer | 300.0 |
| Microcrystalline cellulose | Filler | 120.0 |
| Povidone K30 | Binder | 12.0 |
| Magnesium stearate | Lubricant | 4.0 |
P.2 Pharmaceutical Development (Q8)
- (A) IV: the formulation targets isotonicity and pH 7.4 (near maximum solubility and minimum deamidation/aggregation); polysorbate 80 suppresses interfacial aggregation during manufacture, shipping and pen actuation; phenol enables multidose use (preservative-efficacy USP <51> demonstrated). A justified minor overage and in-use stability support once-weekly multidose pen use.
- (B) Oral: the central development challenge is the very low intrinsic oral bioavailability of peptides. SNAC transiently and locally raises gastric pH and fluidises the epithelial membrane, promoting transcellular monomer absorption in a narrow window; the tablet is engineered for rapid disintegration and a localized high concentration of drug + enhancer. Dosing instructions (fasting, ≤120 mL water, ≥30 min before food) are justified by food-effect and water-volume studies. Robustness to enhancer:drug ratio and to disintegration time was established by a design-of-experiments study; the design space centres on the 300 mg SNAC : 8 mg peptide ratio. Oral bioavailability is low (single-digit %) but reproducible — the basis for the higher oral maintenance dose (8 mg) versus IV (4 mg).
P.3 Manufacture
- (A) IV: compounding under nitrogen → sterile filtration (0.22 µm, redundant) → aseptic fill into cartridges → stoppering/sealing → 100% visual + automated particulate inspection. Aseptic process validated by media fill; filter validation (bacterial retention, extractables, compatibility) provided. Critical parameters: bulk pH, pre-filtration bioburden, fill weight, headspace.
- (B) Oral: direct compression (drug + SNAC + excipients blended, lubricated, compressed) with in-process control of blend uniformity, tablet weight, hardness, thickness, friability and disintegration. Process validated over ≥ 3 batches at commercial scale (M3-PV).
P.4 Control of Excipients
Compendial (Ph.Eur./USP) excipients to monograph; SNAC is controlled to a full internal specification (identity, assay, related substances, residual solvents) as a novel functional excipient with its own characterisation and safety qualification.
P.5 Control of Drug Product
(A) IV solution — specification (illustrative):
| Attribute | Method | Acceptance |
|---|---|---|
| Appearance / colour / clarity | Visual | Clear, colourless–pale-yellow |
| Identity | RP-HPLC + MS | Conforms |
| Assay | RP-HPLC | 95.0–105.0% label |
| Related substances (total / single) | RP-HPLC | ≤ 3.0% / ≤ 1.0% |
| Aggregates | SE-HPLC | ≤ 2.0% |
| pH | potentiometry | 7.2–7.6 |
| Preservative (phenol) content | RP-HPLC | 90–110% |
| Sub-visible particles | USP <788> light obscuration | meets |
| Extractable volume | USP <697> | meets |
| Sterility | USP <71> | sterile |
| Bacterial endotoxins | LAL | ≤ 5 EU/mg |
(B) Oral tablet — specification (illustrative):
| Attribute | Method | Acceptance |
|---|---|---|
| Appearance | Visual | per description |
| Identity | RP-HPLC + MS | Conforms |
| Assay | RP-HPLC | 95.0–105.0% |
| Content uniformity | USP <905> | AV ≤ 15 |
| Dissolution (drug & SNAC) | USP <711>, pH 1.2 → buffer | Q ≥ 80% at 30 min |
| Related substances | RP-HPLC | ≤ 3.0% total |
| Water content | KF | ≤ 6.0% |
| Microbial limits | USP <61>/<62> | meets |
P.5.4 Batch analyses (illustrative)
| Batch | Presentation | Assay | Total RS | Aggregates / Dissolution | Disposition |
|---|---|---|---|---|---|
| DP-IV-001 | IV 4 mg/mL | 99.8% | 1.4% | 0.6% aggregates | Released |
| DP-IV-002 | IV 4 mg/mL | 99.5% | 1.6% | 0.7% aggregates | Released |
| DP-OR-001 | Tablet 8 mg | 99.1% | 1.8% | 94% at 30 min | Released |
| DP-OR-002 | Tablet 8 mg | 98.7% | 2.0% | 92% at 30 min | Released |
| DP-IV-003 | IV 4 mg/mL | 99.6% | 1.5% | 2.4% aggregates (OOS) | Rejected |
Out-of-specification investigation (QA-003 ISS-007): batch DP-IV-003 exceeded the aggregate limit (2.4% vs ≤2.0%). Root cause = a bulk-solution temperature excursion during a hold step (interfacial aggregation, reproduced on challenge). The batch was rejected; CAPA added a bulk-hold temperature CPP with alarmed monitoring and tightened the polysorbate-80 control range (M3-CS §3; M3-PV §3).
P.6 Reference Standards
Common with drug substance (M3-S §S.5).
P.7 Container Closure System
- (A) IV: Type I borosilicate glass cartridge, bromobutyl plunger/septum, in a multidose pen injector; container-closure integrity (dye/microbial ingress) and device functional + extractable/leachable data provided.
- (B) Oral: HDPE bottle with induction seal and silica-gel desiccant (moisture-sensitive enhancer), or alternatively Alu/Alu blister; child-resistant closure.
P.8 Stability (Q1A(R2)/Q1B)
| Presentation | Condition | 0 / 12 / 24 mo (assay) | Total RS | Shelf life |
|---|---|---|---|---|
| IV 4 mg/mL | 5 °C (long-term) | 99.8 → 99.0 → 98.3% | 1.4 → 2.1 → 2.8% | 24 months at 2–8 °C |
| IV 4 mg/mL | 25 °C (in-use/excursion) | 99.8 → 98.0 (6 mo) | 1.4 → 3.0 (6 mo) | in-use 6 wk at ≤30 °C after first use |
| Tablet 8 mg | 25 °C/60% RH | 99.1 → 98.2 → 97.4% | 1.8 → 2.6 → 3.2% | 24 months at ≤30 °C (keep desiccated) |
| Tablet 8 mg | 40 °C/75% RH (accel.) | 99.1 → 96.8 (6 mo) | 1.8 → 4.0 (6 mo) | informs packaging |
Photostability (Q1B) confirmed adequate protection by the container-closure. Degradation is dominated by oxidation/deamidation/aggregation (IV) and moisture-mediated hydrolysis (tablet); both presentations are controlled within the proposed shelf lives (M3-STAB).
Comments (0)
No comments yet. Be the first to say something!